|
Heart failure
|
0.600 |
Biomarker
|
disease |
BEFREE |
BNP, which is synthesized in the cardiac ventricles and correlates with LV pressure, amount of dyspnea, and the state of neurohormonal modulation, makes this peptide the first potential "white count" for heart failure.
|
11715177 |
2001 |
|
Heart failure
|
0.600 |
Biomarker
|
disease |
BEFREE |
BNP may thus contribute to adverse myocardial remodelling in heart failure.
|
19808301 |
2008 |
|
Heart failure
|
0.600 |
AlteredExpression
|
disease |
BEFREE |
Accompanying these effects, tadalafil treatment normalized BNP mRNA and prevented development of subjective signs of HF.
|
31043634 |
2019 |
|
Heart failure
|
0.600 |
Biomarker
|
disease |
BEFREE |
Atrial and brain natriuretic peptides (ANP and BNP) are established diagnostic and prognostic markers in heart failure, but their utility in patients with advanced cancer is unclear.
|
31128228 |
2019 |
|
Heart failure
|
0.600 |
Biomarker
|
disease |
BEFREE |
Baseline BNP; subsequent hospitalization for heart failure or death.
|
28768311 |
2017 |
|
Heart failure
|
0.600 |
AlteredExpression
|
disease |
BEFREE |
Baseline rSO2 was lower in patients with heart failure (45.2±8.3 % vs. 54.1±7.8 %, p=0.006) and was significantly linked to higher red cell distribution width (RDW) (r=-0.53, p?0.001) and higher BNP level (r=-0.45, p=0.01).
|
31177793 |
2019 |
|
Heart failure
|
0.600 |
Biomarker
|
disease |
BEFREE |
Because NE and BNP are considered as neurohormones indicating heart failure progression, we also determined the levels of plasma NE and BNP-45 besides cardiac function.
|
29879885 |
2018 |
|
Heart failure
|
0.600 |
AlteredExpression
|
disease |
BEFREE |
Brain natriuretic peptide (BNP) gene expression accompanies cardiac hypertrophy and heart failure.
|
11230322 |
2001 |
|
Heart failure
|
0.600 |
Therapeutic
|
disease |
CTD_human |
Brain natriuretic peptide is a predictor of anthracycline-induced cardiotoxicity.
|
11279304 |
2000 |
|
Heart failure
|
0.600 |
Biomarker
|
disease |
CTD_human |
Brain natriuretic peptide is a predictor of anthracycline-induced cardiotoxicity.
|
11279304 |
2000 |
|
Heart failure
|
0.600 |
GeneticVariation
|
disease |
BEFREE |
By multiple linear regression analysis adjusted for age and sex, heart failure (HF) and BNP strongly associated with sST2 concentration.
|
29428199 |
2018 |
|
Heart failure
|
0.600 |
Biomarker
|
disease |
BEFREE |
Cardiac biomarkers troponin and brain natriuretic peptide/N-terminal proBNP (BNP/NT-proBNP) have been extensively studied in heart failure and acute coronary syndromes.
|
30701097 |
2018 |
|
Heart failure
|
0.600 |
Biomarker
|
disease |
CTD_human |
Carvedilol modulates the expression of hypoxia-inducible factor-1alpha and vascular endothelial growth factor in a rat model of volume-overload heart failure.
|
15732037 |
2005 |
|
Heart failure
|
0.600 |
Therapeutic
|
disease |
CTD_human |
Carvedilol modulates the expression of hypoxia-inducible factor-1alpha and vascular endothelial growth factor in a rat model of volume-overload heart failure.
|
15732037 |
2005 |
|
Heart failure
|
0.600 |
Biomarker
|
disease |
BEFREE |
Change of BNP between admission and discharge after ST-elevation myocardial infarction (Killip I) improves risk prediction of heart failure, death, and recurrent myocardial infarction compared to single isolated measurement in addition to the GRACE score.
|
29359586 |
2019 |
|
Heart failure
|
0.600 |
Biomarker
|
disease |
CTD_human |
Changes in brain natriuretic peptide and norepinephrine over time and mortality and morbidity in the Valsartan Heart Failure Trial (Val-HeFT).
|
12628948 |
2003 |
|
Heart failure
|
0.600 |
Therapeutic
|
disease |
CTD_human |
Changes in brain natriuretic peptide and norepinephrine over time and mortality and morbidity in the Valsartan Heart Failure Trial (Val-HeFT).
|
12628948 |
2003 |
|
Heart failure
|
0.600 |
Therapeutic
|
disease |
CTD_human |
Clinical and hemodynamic effects of nesiritide (B-type natriuretic peptide) in patients with decompensated heart failure receiving beta blockers.
|
15860969 |
2005 |
|
Heart failure
|
0.600 |
Biomarker
|
disease |
CTD_human |
Clinical and hemodynamic effects of nesiritide (B-type natriuretic peptide) in patients with decompensated heart failure receiving beta blockers.
|
15860969 |
2005 |
|
Heart failure
|
0.600 |
Biomarker
|
disease |
LHGDN |
Clinical significance of N-terminal-probrain natriuretic peptide in hypertrophic cardiomyopathy.
|
17879024 |
2007 |
|
Heart failure
|
0.600 |
Biomarker
|
disease |
BEFREE |
Clinical trials have documented the benefits and risks of the use of synthetic ANP (Anaritide) and BNP (Nesiritide) for treating heart failure, renal failure, and hypertension.
|
20433683 |
2011 |
|
Heart failure
|
0.600 |
GeneticVariation
|
disease |
BEFREE |
Common genetic variants reported to be associated with BNP levels were not associated with a relevant risk of heart failure in our population-based cohort.
|
23315043 |
2013 |
|
Heart failure
|
0.600 |
AlteredExpression
|
disease |
BEFREE |
Conclusions Analytical performances of the BNP and PBNP ADVIA methods are well in accordance with the quality specifications required by international guidelines for diagnosis and follow-up of patients with HF.
|
30412461 |
2019 |
|
Heart failure
|
0.600 |
Biomarker
|
disease |
BEFREE |
Currently, N-terminal pro-B-type natriuretic peptide (NT-proBNP) and its physiologically active counterpart, BNP, are most frequently used as biomarkers for diagnosis, prognosis, and disease monitoring of heart failure (HF).
|
28062629 |
2017 |
|
Heart failure
|
0.600 |
Biomarker
|
disease |
BEFREE |
Daily home BNP monitoring in heart failure for prediction of impending clinical deterioration: results from the HOME HF study.
|
29314505 |
2018 |